LumiraDx and cobas® liat analyser provide a comprehensive portfolio to aid you in the differential diagnosis of SARS-CoV-2, Influenza A/B and RSV.9-15
Roche Respiratory Solutions in the UK and Ireland
Roche Total Respiratory Solutions
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
Helping you transform what's possible with respiratory testing
Roche Respiratory Solutions can assist experts in diagnosing, correctly treating, and discharging patients faster, potentially easing the burden on healthcare professionals and helping to reduce winter pressures.
Rapid respiratory test results help empower clinicians to deliver treatment at the earliest possible stage – potentially reducing the risk of escalation and improving patient outcomes.
The Roche solution includes tests, technologies and transformation support for introducing rapid respiratory testing into any clinical setting - bringing care closer to the patient.
Enhancing care across all pathways
Our respiratory solutions are proven to deliver accurate diagnostics where they are needed most; in the community, in clinics, in hospitals, and helping to protect high-risk patients.
Respiratory Testing in Primary Care
Quick, targeted near-patient respiratory testing in the community, clinics and point of entry.
The primary care setting plays a critical role in the diagnosis and management of respiratory infections, with respiratory symptoms being the most common reason for primary care consultations.1
LumiraDx
LumiraDx is designed to make testing easy, efficient and more accessible.
Portable battery-operated system
Rapid results in 12 minutes or less
- Additional assays beyond respiratory
cobas® liat analyser
The cobas® liat analyser delivers gold-standard PCR testing at the point of care.
Quick, targeted near-patient testing
Actionable results in 20 minutes.
Frontline multiplex assays
Benefits of rapid respiratory testing in primary care
For a new testing pathway to be adopted at local, regional or national level, it will have to show benefits for the patient, the clinical team and the healthcare system. Rapid respiratory point of care testing in primary care may help to improve diagnosis, clinician confidence, and patient satisfaction.
Rapid diagnosis and treatment
The availability of rapid diagnostic results may increase clinicians' confidence in the diagnosis and enable them to offer appropriate advice, guidance, and treatment at the right time and place.3,4,7
Clinical decision support
Empowering doctors with on-the-spot insights to differentiate bacterial from viral infections may help improve prescribing accuracy and thereby reduce inappropriate antibiotic prescribing.4,5
Fewer secondary care referals
Point of Care testing may help reduce unnecessary referrals, potentially streamlining patient management, alleviating pressure on secondary care and improving patient satisfaction.6,8
Potential cost-saving efficiencies
Appropriate use of Point of Care testing facilitates early diagnosis and treatment that may lead to better outcomes, thereby reducing need for secondary care and helping reduce overall cost of care.6,7
Developing rapid respiratory testing for primary care settings
Access to diagnostics in the community can be powerful. We know that getting a diagnosis quickly can help patients receive effective treatment, but this doesn’t always happen.
Roche has been involved in several pilots to assess the impact of rapid respiratorytesting for primary care settings, bringing testing closer to patients.
Flu Test & Treat Community Pathway
Explore how a flu patient community pathway pilot in Yorkshire and the North West achieved significant results with point-of-care testing. This infographic highlights the project's key outcomes, including estimated reductions in hospital admissions and ICU stays. Download the infographic to learn more about the initiative's impact on healthcare practices.
Acute Respiratory Hub Pathway Evaluation
Discover the benefits of integrating rapid point of care tests in Acute Respiratory Infection (ARI) hubs. Our infographic provides valuable insights on how diagnostic results influence prescribing decisions and patient management, based on a pilot evaluation conducted in partnership with Copeland Primary Care Network. Download the infographic to learn more.
A Rapid Flu Test-And-Treat Community Pathway
A rapid ‘test and treat’ influenza (flu) community pathway incorporating a rapid diagnostic point of care test (POCT) was found to enhance clinical decision-making and thus reduce unnecessary antibiotic use and enable timely antiviral treatment to decrease the impact of infectious diseases and antimicrobial resistance. Download publication to learn more.
Featured products
IVD
For in vitro diagnostic use.
cobas® liat system
The cobas® liat analyzer is an automated nucleic acid test instrument, that when used together with cobas® liat assay tubes to perform in vitro diagnostic tests, is referred to as the cobas® liat system. In conjunction with a cobas® liat assay tube, the instrument performs reagent preparation, target enrichment, inhibitor removal, nucleic acid extraction, polymerase chain reaction (PCR) amplification, real-time detection, and result interpretation to automate the detection or quantification of nucleic acid targets in a biological sample.
Addition for Canada only:
The cobas® liat system is intended for professional use in a clinical laboratory setting or Point of Care (POC) location.
IVD
For in vitro diagnostic use.
LumiraDx Instrument
Discover LumiraDx's advanced point-of-care diagnostic system - fast, accurate, and portable testing for better patient outcomes. Learn more today!
You might be interested in
Benefits of rapid respiratory testing in primary care
Dr Chris Turner explores the evidence around the benefits and impact of near patient testing in primary care. Evidence shows point of care testing (POC) is a cost-effective way to diagnose patients faster than ever, helping empower doctors with the diagnostic confidence to make the best treatment decisions for each patient.
Dr Chris Turner explores the evidence around the benefits and impact of near patient testing in primary care. Evidence shows point of care testing (POC) is a cost-effective way to diagnose patients faster than ever, helping empower doctors with the diagnostic confidence to make the best treatment decisions for each patient.
Assessing the impact of respiratory conditions on the NHS
Managing respiratory infections affects everyone who relies on healthcare systems.
Managing respiratory infections affects everyone who relies on healthcare systems.
Unlocking the potential of point-of-care diagnostic testing
A health service transformation expert, Sheila helped lead several point-of-care respiratory testing pilots across the UK.
A health service transformation expert, Sheila helped lead several point-of-care respiratory testing pilots across the UK.
Creating an integrated respiratory testing solution
Respiratory illnesses – including seasonal flu epidemics, RSV, Strep A and COVID-19 (SARS-CoV-2) – pose considerable challenges to NHS primary and secondary care providers.1
Respiratory illnesses – including seasonal flu epidemics, RSV, Strep A and COVID-19 (SARS-CoV-2) – pose considerable challenges to NHS primary and secondary care providers.1
...
Respiratory Testing in Hospital Wards & Point of Entry
Fast, reliable and robust respiratory testing.
Every hospital admission in winter - whether through A&E or onto a ward.
LumiraDx
LumiraDx is designed to make testing easy, efficient and more accessible.
Portable battery-operated system
Rapid results in 12 minutes or less
- Additional assays beyond respiratory
cobas® liat analyser
The cobas® liat analyser delivers gold-standard PCR testing at the point of care.
Quick, targeted near-patient testing
Actionable results in 20 minutes.
Frontline multiplex assays
LumiraDx and cobas® liat analyser provide a comprehensive portfolio to aid you in the differential diagnosis of SARS-CoV-2, Influenza A/B and RSV.9-15
Targeted near-patient testing
?wid=402&fmt=png-alpha&fit=crop,1)
Rapid results
Additional assays
Featured products
IVD
For in vitro diagnostic use.
cobas® liat system
The cobas® liat analyzer is an automated nucleic acid test instrument, that when used together with cobas® liat assay tubes to perform in vitro diagnostic tests, is referred to as the cobas® liat system. In conjunction with a cobas® liat assay tube, the instrument performs reagent preparation, target enrichment, inhibitor removal, nucleic acid extraction, polymerase chain reaction (PCR) amplification, real-time detection, and result interpretation to automate the detection or quantification of nucleic acid targets in a biological sample.
Addition for Canada only:
The cobas® liat system is intended for professional use in a clinical laboratory setting or Point of Care (POC) location.
IVD
For in vitro diagnostic use.
LumiraDx Instrument
Discover LumiraDx's advanced point-of-care diagnostic system - fast, accurate, and portable testing for better patient outcomes. Learn more today!
You might be interested in
Introducing Roche Total Respiratory Solution
Roche has developed a comprehensive range of rapid respiratory tests, technologies and assays for primary, secondary and community care settings. We are helping the NHS to transform what’s possible with respiratory testing.
Roche has developed a comprehensive range of rapid respiratory tests, technologies and assays for primary, secondary and community care settings. We are helping the NHS to transform what’s possible with respiratory testing.
Assessing the impact of respiratory conditions on the NHS
Managing respiratory infections affects everyone who relies on healthcare systems.
Managing respiratory infections affects everyone who relies on healthcare systems.
Creating an integrated respiratory testing solution
Respiratory illnesses – including seasonal flu epidemics, RSV, Strep A and COVID-19 (SARS-CoV-2) – pose considerable challenges to NHS primary and secondary care providers.1
Respiratory illnesses – including seasonal flu epidemics, RSV, Strep A and COVID-19 (SARS-CoV-2) – pose considerable challenges to NHS primary and secondary care providers.1
...
Respiratory Testing in Hospitals
High-throughput molecular diagnostic testing.
Roche cobas® 5800, 6800 and 8800 systems aim to consolidate up to 90% of routine molecular testing into a single workflow,2 enabling under-pressure lab staff to focus on adding value in other areas.
Roche’s advanced cobas® Respiratory flex is a flexible, high-throughput, syndromic test that can be customised by clinicians. They can order respiratory tests that are optimised for settings and address seasonality, local dynamics and patient cohort.
Flexible syndromic testing
High-throughput multiplex
?wid=402&fmt=png-alpha&fit=crop,1)
Reliable and robust
Featured products
IVD
For in vitro diagnostic use.
cobas® 5800 System
The cobas® 5800 System makes automation, consolidation, integration and standardization more accessible than ever before.
IVD
For in vitro diagnostic use.
cobas® 6800 System
Embrace the future of molecular testing with proven PCR performance. Learn about the cobas® 6800 System’s broad menu of high-quality assays, including HIV, HPV, CT/NG, Hepatitis, CMV, WNV, respiratory infections, and more!
IVD
For in vitro diagnostic use.
cobas® 8800 System
Run up to 1,056 tests in an 8-hour shift and experience unparalleled automation - only 3 user interactions per run for up to 4 hours of walk-away time.
You might be interested in
Introducing Roche Total Respiratory Solution
Roche has developed a comprehensive range of rapid respiratory tests, technologies and assays for primary, secondary and community care settings. We are helping the NHS to transform what’s possible with respiratory testing.
Roche has developed a comprehensive range of rapid respiratory tests, technologies and assays for primary, secondary and community care settings. We are helping the NHS to transform what’s possible with respiratory testing.
Assessing the impact of respiratory conditions on the NHS
Managing respiratory infections affects everyone who relies on healthcare systems.
Managing respiratory infections affects everyone who relies on healthcare systems.
Creating an integrated respiratory testing solution
Respiratory illnesses – including seasonal flu epidemics, RSV, Strep A and COVID-19 (SARS-CoV-2) – pose considerable challenges to NHS primary and secondary care providers.1
Respiratory illnesses – including seasonal flu epidemics, RSV, Strep A and COVID-19 (SARS-CoV-2) – pose considerable challenges to NHS primary and secondary care providers.1
cobas® Respiratory flex
Introducing the cobas® Respiratory flex assay, designed to enhance your diagnostic capabilities with Roche-developed innovative TAGS (temperature activated generation of signal) technology.
Introducing the cobas® Respiratory flex assay, designed to enhance your diagnostic capabilities with Roche-developed innovative TAGS (temperature activated generation of signal) technology.
...
Respiratory Testing for High-Risk Patients
Precision respiratory testing.
In complex cases, clinicians need diagnostic confidence to help enable them to select the most appropriate treatment and make informed prescribing decisions.
Roche cobas® eplex can perform rapid syndromic diagnosis, testing a single sample for 20 conditions and delivering a result in 90 minutes.
Tests 20+ respiratory targets
?wid=402&fmt=png-alpha&fit=crop,1)
Easy to use workflow
?wid=402&fmt=png-alpha&fit=crop,1)
Urgent results for high-risk patients
Featured products
IVD
For in vitro diagnostic use.
ePlex® system
The ePlex system is used to run multiplex microarray-based assays developed by GenMark. This type of assay is based on the principles of competitive nucleic acid hybridization using a sandwich assay format, wherein a single-stranded target binds concurrently to a sequence-specific solution-phase signal probe and a solid-phase electrode-bound capture probe. The test employs nucleic acid extraction, target amplification via polymerase chain reaction (PCR) or reverse transcription PCR (RT-PCR) and hybridization of target DNA. In the process, the double-stranded PCR amplicons are digested with exonuclease to generate single-stranded DNA suitable for hybridization.
References
1. Abdel-Aal A et al. Prioritising primary care respiratory research needs: results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise. NPJ Prim Care Respir Med. 2022 Jan 28;32:6.
2. (2024). Roche. Available at: https://diagnostics.roche.com/global/en/products/instruments/cobas-8800-ins-2694.html (Accessed: 2 October 2024).
3. Cooke J, et al. BMJ Open Resp Res. 2015;2:e000086.
4. Lingervelder D, et al. Int J Clin Pract. 2019;73:e13392.
5. Thornton HV, et al. British Journal of General Practice. 2020;70(701):574-575.
6. Schols AMR, et al. British Journal of General Practice. 2018;68(673):362-363.
7. Mills SEE, et al. BJGP Open. 2024;8(2):BJGPO.2023.0094.
8. Turner PJ, et al. Family Practice. 2016;33(4):388–394.
9. LumiraDx Product Insert SARS-CoV-2 Ag (version 14, 2022)
10. LumiraDx Product Insert SARS-CoV-2 Ag Ultra (version 1, 2022-07)
11. LumiraDx Product Insert SARS-CoV-2 & Flu A/B (version 5, 2022)
12. LumiraDx Product Insert SARS-CoV-2 & RSV (version 3, 2023-08)
13. cobas® Influenza A/B & RSV Product Insert
14. cobas® SARS-C0V-2 Product Insert
15. cobas® SARS-C0V-2 & Influenza A/B Product Insert